Cargando…

Identification of New Players in Hepatocarcinogenesis: Limits and Opportunities of Using Tissue Microarray (TMA)

Liver tumours are among the leading causes of cancer-related death worldwide and hepatocellular carcinoma (HCC) accounts for the vast majority of liver tumours. When detected at an early stage of disease, patients might still be eligible for surgical-based curative treatments. However, currently onl...

Descripción completa

Detalles Bibliográficos
Autores principales: Quagliata, Luca, Schlageter, Manuel, Quintavalle, Cristina, Tornillo, Luigi, Terracciano, Luigi M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5003443/
https://www.ncbi.nlm.nih.gov/pubmed/27600338
http://dx.doi.org/10.3390/microarrays3020091
_version_ 1782450647645290496
author Quagliata, Luca
Schlageter, Manuel
Quintavalle, Cristina
Tornillo, Luigi
Terracciano, Luigi M.
author_facet Quagliata, Luca
Schlageter, Manuel
Quintavalle, Cristina
Tornillo, Luigi
Terracciano, Luigi M.
author_sort Quagliata, Luca
collection PubMed
description Liver tumours are among the leading causes of cancer-related death worldwide and hepatocellular carcinoma (HCC) accounts for the vast majority of liver tumours. When detected at an early stage of disease, patients might still be eligible for surgical-based curative treatments. However, currently only small portion of HCC affected patients are diagnosed at an early stage. For late stage HCC no treatment option exists beside the multi-tyrosine kinase inhibitor Sorafenib. Thus new molecular targets and treatment options for HCC are urgently needed. Nevertheless, despite some improvements in diagnosis and patient management, the biology of liver tumour remains inadequately understood, mainly because these tumours have shown to harbour a highly complex genomic landscape. In addition, one major obstacle delaying the identification of new molecular targets in biomedical research is the necessity to validate them using a large collection of tissue specimens. Tissue microarray (TMA) technology allows the prompt molecular profiling of multiple tissue specimens and is therefore ideal to analyze presumptive candidate biomarkers in a fast an effective manner. The use of TMA has substantial benefits over standard techniques and represents a significant advancement in molecular pathology. For example, TMA technology reduces laboratory work, offers a high level of experimental uniformity and provides a judicious use of precious tissue. On the other hand, one potential limitation of using TMA is that the small cores sampled may not be representative of whole tumors. This issue is very critical in particularly heterogeneous cancers such as HCC. For liver focused studies, it is ideal to evaluate the staining patters of a determined marker over the structure of an entire acinus and to define staining in as many as possible anatomical regions. In this review we analyze the limits and opportunities offered by the usage of TMA technology in HCC research. In summary, TMA has revolutionized the histopathological analysis and will be of great help to further advance the knowledge in the field of hepatocarcinogenesis research.
format Online
Article
Text
id pubmed-5003443
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-50034432016-09-06 Identification of New Players in Hepatocarcinogenesis: Limits and Opportunities of Using Tissue Microarray (TMA) Quagliata, Luca Schlageter, Manuel Quintavalle, Cristina Tornillo, Luigi Terracciano, Luigi M. Microarrays (Basel) Review Liver tumours are among the leading causes of cancer-related death worldwide and hepatocellular carcinoma (HCC) accounts for the vast majority of liver tumours. When detected at an early stage of disease, patients might still be eligible for surgical-based curative treatments. However, currently only small portion of HCC affected patients are diagnosed at an early stage. For late stage HCC no treatment option exists beside the multi-tyrosine kinase inhibitor Sorafenib. Thus new molecular targets and treatment options for HCC are urgently needed. Nevertheless, despite some improvements in diagnosis and patient management, the biology of liver tumour remains inadequately understood, mainly because these tumours have shown to harbour a highly complex genomic landscape. In addition, one major obstacle delaying the identification of new molecular targets in biomedical research is the necessity to validate them using a large collection of tissue specimens. Tissue microarray (TMA) technology allows the prompt molecular profiling of multiple tissue specimens and is therefore ideal to analyze presumptive candidate biomarkers in a fast an effective manner. The use of TMA has substantial benefits over standard techniques and represents a significant advancement in molecular pathology. For example, TMA technology reduces laboratory work, offers a high level of experimental uniformity and provides a judicious use of precious tissue. On the other hand, one potential limitation of using TMA is that the small cores sampled may not be representative of whole tumors. This issue is very critical in particularly heterogeneous cancers such as HCC. For liver focused studies, it is ideal to evaluate the staining patters of a determined marker over the structure of an entire acinus and to define staining in as many as possible anatomical regions. In this review we analyze the limits and opportunities offered by the usage of TMA technology in HCC research. In summary, TMA has revolutionized the histopathological analysis and will be of great help to further advance the knowledge in the field of hepatocarcinogenesis research. MDPI 2014-04-15 /pmc/articles/PMC5003443/ /pubmed/27600338 http://dx.doi.org/10.3390/microarrays3020091 Text en © 2014 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/3.0/).
spellingShingle Review
Quagliata, Luca
Schlageter, Manuel
Quintavalle, Cristina
Tornillo, Luigi
Terracciano, Luigi M.
Identification of New Players in Hepatocarcinogenesis: Limits and Opportunities of Using Tissue Microarray (TMA)
title Identification of New Players in Hepatocarcinogenesis: Limits and Opportunities of Using Tissue Microarray (TMA)
title_full Identification of New Players in Hepatocarcinogenesis: Limits and Opportunities of Using Tissue Microarray (TMA)
title_fullStr Identification of New Players in Hepatocarcinogenesis: Limits and Opportunities of Using Tissue Microarray (TMA)
title_full_unstemmed Identification of New Players in Hepatocarcinogenesis: Limits and Opportunities of Using Tissue Microarray (TMA)
title_short Identification of New Players in Hepatocarcinogenesis: Limits and Opportunities of Using Tissue Microarray (TMA)
title_sort identification of new players in hepatocarcinogenesis: limits and opportunities of using tissue microarray (tma)
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5003443/
https://www.ncbi.nlm.nih.gov/pubmed/27600338
http://dx.doi.org/10.3390/microarrays3020091
work_keys_str_mv AT quagliataluca identificationofnewplayersinhepatocarcinogenesislimitsandopportunitiesofusingtissuemicroarraytma
AT schlagetermanuel identificationofnewplayersinhepatocarcinogenesislimitsandopportunitiesofusingtissuemicroarraytma
AT quintavallecristina identificationofnewplayersinhepatocarcinogenesislimitsandopportunitiesofusingtissuemicroarraytma
AT tornilloluigi identificationofnewplayersinhepatocarcinogenesislimitsandopportunitiesofusingtissuemicroarraytma
AT terraccianoluigim identificationofnewplayersinhepatocarcinogenesislimitsandopportunitiesofusingtissuemicroarraytma